Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05133323 · ClinicalTrials.gov registry record · Phase 2
A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
A Phase 2 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 237
- Enrollment target
NCT05133323 is a Phase 2 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 237 participants.
The verdict
NCT05133323, a Phase 2 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 237 participants
- Enrollment target
Study Summary
Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines. People who join this trial have tried 2 to 4 other medications to prevent their migraines, but these medications have not helped them. When the trial is over, researchers will use this information to find out if the number of migraine days decreased more for the participants who got either dose of Lu AG09222 than for the participants who got the placebo.
Interventions
- DRUG Placebo
- DRUG Lu AG09222
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2021-11-11 |
| Est. Completion | 2023-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05133323
The ClinicalTrials.gov registry entry for NCT05133323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05133323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05133323 about?
NCT05133323 is a clinical study titled "A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments". Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines. People who join this trial have tried 2 to 4 other medications to prevent their migraines, but these medic...
What is the current status of trial NCT05133323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 237 participants. The study started on 2021-11-11. Estimated completion is 2023-03-16.
What interventions are being tested in trial NCT05133323?
The interventions under investigation include: Placebo (DRUG), Lu AG09222 (DRUG).
Who is sponsoring clinical trial NCT05133323?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.